AMRN — Amarin Corporation plc

Amarin Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Revenue: $45.1 million, up from $42 million in Q1 2025.
• U.S. Revenue: Consistent with Q1 2025; volume increased due to regained exclusive status with a pharmacy benefit manager (PBM).
• European Revenue: $4.9 million, down from $5.4 million in Q1 2025 but up 113% from $2.3 million in Q4 2025.
• Rest of World Revenue: $2.8 million, with no revenue in Q1 2025.
• Operating Expenses: Declined by 31% to $29.1 million; excluding restructuring charges, a 38% decline to $25.8 million.
• Operating Loss: Narrowed to $11.3 million from $16.8 million in Q1 2025; adjusted loss (excluding restructuring) was $8 million.
• Cash Position: $308 million, up from $303 million at year-end 2025; no debt and positive cash flow from operations of $6.4 million for the second consecutive quarter.

2. Strategic Updates and Business Highlights

• Global Restructuring: Nearly complete, with anticipated savings of $70 million by June 30, 2026.
• New Operating Model: Transitioned to a dual business model with a U.S. commercial focus and a partnered international strategy, primarily with Recordati in Europe.
• VASCEPA Performance: Continued market leadership in the U.S. with a 48% market share; branded prescriptions rose by 17% year-over-year.
• International Expansion: Positive early sales trends in Europe and other markets, with launches planned in South Korea and Singapore in early 2027.

3. Forward Guidance and Outlook

• Positive Cash Flow: Expected to continue throughout 2026, contingent on maintaining exclusive contracts.
• Operating Expense Management: Anticipated stability in operating expenses, with a focus on maintaining a lower cost structure.
• Market Positioning: VASCEPA is well-positioned to benefit from updated clinical guidelines that emphasize triglyceride management in cardiovascular risk.

4. Bad News, Challenges, or Points of Concern

• U.S. Revenue Pressure: Continued revenue declines due to generic competition, although VASCEPA remains the market leader.
• Price Sensitivity: U.S. net pricing may face challenges due to annual payer changes.
• Dependence on Partnerships: Revenue variability expected from the international commercial model, influenced by launch timing and market demand.

5. Notable Q&A Insights

• U.S. Pricing Trends: Management expects U.S. net pricing to remain stable but acknowledges potential impacts from changes in exclusive contracts.
• Cash Flow Sustainability: Confidence expressed in maintaining positive cash flow beyond 2026, driven by strategic contract management.
• Guideline Impact: Positive qualitative feedback from physicians regarding updated guidelines, but quantifiable growth impacts may take time to materialize.
• Authorized Generic Strategy: No immediate plans to launch an authorized generic; the current strategy is yielding profitable results in the U.S.

Overall, Amarin's Q1 2026 results reflect a solid financial position and strategic progress, particularly in international markets, while facing ongoing challenges in the U.S. due to competitive pressures.